A Comprehensive Review of Alzheimer’s Disease

Alzheimer's disease is a progressively deteriorating condition that mainly affects memory, cognitive abilities, and behavior. It is the most common cause of dementia in older adults and gradually impairs daily functioning and the capacity to live independently. In 1906, Alois Alzheimer was the first to identify the disease.

Alzheimer’s disease is characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain, leading to neuronal damage and cognitive decline. Symptoms typically begin with mild memory loss and confusion and may progress to a noticeable decline in language, judgment, and personality. Age, inherited susceptibility, blood vessel problems, and the accumulation of abnormal proteins are major contributors to the disease. In many patients, Alzheimer’s disease appears alongside other neurological conditions such as cerebrovascular disease and Lewy body pathology, making diagnosis and treatment more complex. Despite extensive research, no permanent cure currently exists, making early diagnosis and effective management critically important. [1] to [7]

ETIOLOGY AND RISK FACTORS

Genetic Factors

Alzheimer's disease is associated with several genetic abnormalities that contribute to its development. Mutations in the APP, PSEN1, and PSEN2 genes are linked to early-onset familial Alzheimer’s disease, while the APOE ε4 allele is considered the most important genetic risk factor for late-onset Alzheimer’s disease. These genetic changes result in an abnormal accumulation of amyloid-beta protein in the brain.[ 8]

Age as a Major Risk Factor

Advancing age is the leading risk factor for Alzheimer’s disease. The risk rises significantly after age 65 and climbs quickly in older adults. As the body ages, neurons slowly decline, brain repair mechanisms grow less efficient, and the brain becomes more vulnerable to the accumulation of abnormal proteins.[9]

Lifestyle and Environmental Influences

Certain lifestyle-related conditions can increase the risk of developing Alzheimer’s disease. Hypertension, diabetes mellitus, obesity, smoking, sedentary lifestyle, poor diet, and cardiovascular diseases are strongly associated with cognitive decline. Head injuries, chronic stress, and lack of mental stimulation may also contribute to the progression of the disease.[10]

Cellular and Molecular Factors

Neuroinflammation, oxidative stress, mitochondrial dysfunction, and vascular problems are major factors in the onset of Alzheimer’s disease. These processes damage neurons, interfere with synaptic communication, and accelerate neuronal death. The accumulation of amyloid-beta plaques and tau protein tangles further speeds up brain degeneration. [11]

Protective Factors

Certain healthy lifestyle habits may reduce the risk or delay the onset of Alzheimer’s disease. Regular exercise, a nutritious diet, mental engagement, social interaction, and proper management of chronic conditions may promote brain health and potentially slow cognitive decline. [12]

PATHOPHYSIOLOGY OF ALZHEIMER’S DISEASE

Formation of Amyloid-Beta Plaques

A major pathological feature of Alzheimer's disease is the accumulation of amyloid-beta Aβ) protein in the brain. The amyloid precursor protein ( APP) undergoes abnormal cleavage, producing insoluble amyloid-beta peptides that build up into extracellular plaques. These plaques disrupt neuronal communication, trigger inflammation, and result in neuronal death. [13]

Neurofibrillary Tangles

Neurofibrillary tangles are made up of tau protein that has been abnormally phosphorylated and accumulates inside cells. Normally, tau supports microtubule stability in neurons, but in Alzheimer’s disease, it becomes defective and forms paired helical filaments inside neurons. This disrupts axonal transport and leads to neuronal dysfunction and degeneration. [14]

Synaptic Dysfunction and Neuronal Loss

The loss of synapses is considered one of the main factors leading to cognitive decline in Alzheimer’s disease. Amyloid-beta toxicity and tau abnormalities interfere with synaptic transmission and neuronal signaling, leading to progressive neuronal death, especially in the hippocampus and cerebral cortex. [15]

Neuroinflammation

Microglia and astrocytes get activated in response to amyloid-beta buildup. Ongoing neuroinflammation leads to the release of inflammatory agents and oxidative molecules, worsening neuronal damage and speeding up disease advancement.[16]

Oxidative Stress and Mitochondrial Dysfunction

Oxidative stress, caused by an excess of reactive oxygen species, causes damage to cellular proteins, lipids, and DNA. Mitochondrial dysfunction reduces energy production in neurons and increases their vulnerability, contributing to cognitive decline. [17]

Changes in the Cerebrovascular System

Conditions such as reduced cerebral blood flow, small vessel disease, and cerebral amyloid angiopathy result in less oxygen and nutrients reaching the brain. These vascular changes interact with Alzheimer’s disease pathology to accelerate cognitive decline.[18]

Brain Atrophy

The progressive loss of neurons leads to a decrease in brain tissue, particularly in the hippocampus, temporal lobe, and cerebral cortex. Brain atrophy is strongly associated with memory loss, diminished reasoning skills, and more pronounced dementia symptoms.[19]

CLINICAL MANIFESTATIONS

Memory Impairment

The most common and earliest indicator of Alzheimer's disease is a slowly progressing decline in memory. Initially, patients find it difficult to remember recent events, conversations, appointments, and new information. As the disease advances, long-term memory is also affected.[20]

Decline in Cognitive Function

Patients gradually lose their capacity to think, reason, judge, and solve problems. Difficulty focusing, confusion regarding time and location, and challenges with complex tasks are commonly observed. [21]

Problems with Language and Communication

Alzheimer’s disease affects language skills, causing difficulty in recalling words, understanding conversations, reading, and writing. Patients may repeat questions or struggle to maintain effective communication.[22]

Behavioral and Psychological Symptoms

As the disease progresses, behavioral disturbances such as depression, anxiety, irritability, aggression, mood swings, hallucinations, and social withdrawal are commonly seen. Sleep disturbances and emotional instability may also occur. [23]

Functional Impairment

As cognitive decline progresses, patients lose the ability to carry out daily activities on their own. Challenges arise in getting dressed, eating, keeping up personal hygiene, managing money, and handling medications. [24]

Motor and Neurological Symptoms

In later stages, patients may develop poor coordination, difficulty walking, stiff muscles, and trouble swallowing. Some individuals may also experience seizures or Parkinsonian symptoms.[25]

Stages of Alzheimer’s Disease

The clinical progression of Alzheimer’s disease is generally divided into mild, moderate, and severe stages. Mild disease is characterized by memory issues and slight cognitive changes; moderate disease causes more confusion and a loss of ability to manage daily activities independently, while severe disease results in complete dependence and an inability to communicate. [26]

DIAGNOSIS OF ALZHEIMER’S DISEASE

Clinical Evaluation

The diagnosis of Alzheimer's disease begins with a comprehensive review of the patient's medical history and a clinical assessment.

Doctors evaluate memory problems, changes in behavior, decline in cognitive function, and the patient’s ability to perform daily activities. Family history and the onset of symptoms are also considered. [27]

Cognitive and Neuropsychological Tests

Various cognitive assessments are used to measure memory, language, attention, reasoning, and problem-solving abilities. Commonly used tools include the Mini-Mental State Examination ( MMSE) and the Montreal Cognitive Assessment (MoCA). These tests help evaluate the degree of cognitive impairment. [28]

Neurological and Physical Assessment

The neurological exam evaluates reflexes, coordination, sensory function, balance, and motor abnormalities. A physical exam can also help exclude other medical conditions that may mimic dementia symptoms.[29]

Techniques for Brain Imaging

Imaging methods such as computed tomography (CT) scans and magnetic resonance imaging ( MRI) are used to detect brain atrophy, especially in the hippocampus and cerebral cortex. Positron emission tomography ( PET) is capable of identifying amyloid-beta buildup and reduced brain metabolic activity.[30]

Laboratory Investigations

Blood tests are performed to identify reversible causes of cognitive impairment, such as vitamin deficiencies, thyroid problems, infections, or metabolic conditions. Analysis of cerebrospinal fluid ( CSF) may show elevated levels of amyloid-beta and tau proteins associated with Alzheimer’s disease. [31]

Biomarkers

Biomarkers play a vital role in early and accurate diagnosis. PET scans and CSF analyses can detect amyloid-beta accumulation, tau-related changes, and signs of neurodegeneration. These biomarkers are especially useful in the preclinical stages of Alzheimer’s disease. [32]

Differential Diagnosis

Alzheimer’s disease needs to be differentiated from other types of dementia, including vascular dementia, Lewy body dementia, dementia associated with Parkinson’s disease, frontotemporal dementia, and depression. Accurate diagnosis is essential for effective management and treatment planning[33]

TREATMENT AND MANAGEMENT OF ALZHEIMER’S DISEASE

Medication Therapy

Although there is currently no confirmed cure for Alzheimer's disease, several medications can help manage symptoms and slow the progression of the condition. Cholinesterase inhibitors such as Donepezil, Rivastigmine, and Galantamine improve cognitive function by increasing acetylcholine levels in the brain. Memantine is used in moderate to severe cases to regulate glutamate activity and reduce neuronal damage. [34]

Symptomatic and Supportive Therapy

Behavioral and psychological symptoms such as depression, anxiety, agitation, and sleep disturbances may require supportive treatment. Antidepressants, anxiolytics, and antipsychotic medications may be prescribed cautiously when necessary. Counseling and emotional support are also essential for patients and caregivers. [35]

Non-Pharmacological Management

Non-drug approaches are vital for improving quality of life. Cognitive stimulation therapy, memory exercises, physical activity, social engagement, music therapy, and occupational therapy all help maintain mental and functional abilities. Creating a safe and supportive environment helps lessen confusion and stress. [36]

Changes to Lifestyle

Making healthy lifestyle choices may slow down cognitive decline and improve overall brain health. Regular exercise, balanced nutrition, adequate sleep, effective stress management, and appropriate control of chronic conditions such as hypertension and diabetes are strongly recommended. [37]

Support for and Rehabilitation of Caregivers

Caregivers play a vital role in managing Alzheimer’s disease. Grasping how diseases advance, controlling behavior, and acquiring daily care methods are essential. Support groups and respite care programs help reduce the burden and emotional stress on caregivers. [38 ]

Advanced and Emerging Therapies

Current research focuses on disease-modifying therapies targeting amyloid-beta and tau proteins. Immunotherapy, monoclonal antibodies, stem cell therapy, and gene-based treatments are being researched for their ability to slow disease progression.[39 6.7 Long-Term Care In advanced stages, patients usually require constant assistance with eating, mobility, personal hygiene, and communication. In later stages of serious illness, extended nursing care and palliative care may be necessary to maintain comfort and dignity. [40]

HERBAL AND NATURAL APPROACHES IN ALZHEIMER’S DISEASE

Role of Herbal and Natural Therapies

There is growing focus on herbal and natural approaches to managing Alzheimer's disease, thanks to their antioxidant, anti-inflammatory and neuroprotective properties. These therapies may aid in improving memory, cognitive function, and overall brain health, though they are generally used as supportive treatments rather than as definitive cures.[41]

Ginkgo Biloba

Ginkgo biloba is one of the most widely studied herbal remedies for Alzheimer’s disease. It could enhance blood flow to the brain, reduce oxidative stress, and support better memory and cognitive performance. Some studies suggest small benefits in slowing cognitive decline. [42]

Curcumin

Curcumin, the main active compound in turmeric, shows strong antioxidant and anti-inflammatory effects. It might aid in reducing the development of amyloid-beta plaques and neuronal damage. Experimental studies on Alzheimer’s disease suggest that curcumin may provide neuroprotective benefits.[43]

Omega-3 Fatty Acids

Found in fish oil and nuts, omega-3 fatty acids support brain function and help preserve neuronal health. They might assist in alleviating inflammation and improving cognitive performance, especially during the initial phases of cognitive decline. [44]

Green Tea

Green tea contains polyphenols and antioxidants that help protect neurons from oxidative stress. Certain compounds in green tea may also help mitigate the damaging effects of amyloid-beta and improve brain function. [45]

Ashwagandha

Ashwagandha is a widely recognized herbal treatment in traditional medicine, prized for its capacity to support the nervous system and reduce stress. Research suggests that it may improve memory, reduce oxidative damage, and support neuronal regeneration.[46 ]

Lifestyle and Dietary Approaches

Natural management also entails maintaining a healthy lifestyle through balanced nutrition, regular physical activity, meditation, yoga, mental stimulation, and adequate sleep. Eating plenty of fruits, vegetables, whole grains, and antioxidants may help reduce the risk of cognitive decline. [47]

Limitations of Herbal Therapies

Although many herbal and natural products show promising outcomes, scientific evidence regarding their long-term effectiveness and safety is still lacking. Therefore, these therapies should be given under medical supervision and alongside standard treatment approaches.[48]

RECENT ADVANCES AND FUTURE PERSPECTIVES

Advancement in Biomarker Research

Advances in biomarker research have improved the capacity to identify Alzheimer's disease in its early stages. Advanced imaging techniques and cerebrospinal fluid biomarkers allow for the identification of amyloid-beta accumulation, tau-related changes, and neurodegeneration before clinical symptoms appear. Blood-based biomarkers are increasingly gaining acceptance as less invasive diagnostic tools.[49]

Monoclonal Antibody Therapy

New therapies targeting amyloid-beta plaques have drawn significant attention. Monoclonal antibodies such as Aducanumab and Lecanemab are designed to reduce amyloid accumulation in the brain and potentially slow cognitive decline in some patients with early-stage Alzheimer’s disease. [50]

Gene and Stem Cell Therapy

Researchers are studying gene-targeted therapies aimed at addressing the genetic mutations linked to Alzheimer’s disease. Stem cell therapy also holds promise for repairing neurons and rehabilitating damaged brain tissue. Though still in experimental stages, these approaches could potentially provide treatment options in the future. [51]

Artificial intelligence and machine learning

Artificial intelligence and machine learning are increasingly being used for early diagnosis, risk assessment, and the analysis of brain imaging data. Digital cognitive assessment tools and wearable devices may provide more effective methods for monitoring disease progression and patient behavior. [52]

Precision and Personalized Medicine

Future treatment approaches emphasize personalized medicine, customizing therapies based on a patient’s genetic profile, biomarkers, disease progression, and unique personal traits. This method could enhance treatment efficacy while minimizing side effects.[53]

Approaches to Combination Therapy

Researchers are investigating combination therapies designed to concurrently address several disease mechanisms, such as amyloid-beta buildup, tau-induced damage, inflammation, oxidative stress, and synaptic impairment. Employing several treatment methods may lead to improved clinical outcomes compared to depending on just one medication.[54]

Future Challenges and Outlook

Despite considerable advances, challenges remain in early diagnosis, developing cost-effective treatments, and understanding the exact processes that cause disease to advance. Future progress in preventing and managing Alzheimer’s disease will depend on continued research, improved diagnostic techniques, and coordinated, multidisciplinary approaches. [55]

CONCLUSION

Alzheimer’s disease is a progressively deteriorating condition that harms the brain, causing significant declines in memory, cognition, behavior, and the ability to perform daily activities. It is one of the most common causes of dementia and presents a major medical and social challenge worldwide, especially as aging populations grow. The disease stems from complex interplays between genetic, environmental, and biological factors, leading to progressive brain decline and cognitive dysfunction.

Although there is currently no permanent cure for Alzheimer’s disease, early detection and proper management can help slow its advance and improve the quality of life for those affected. All these approaches pharmacological treatment, supportive care, lifestyle changes, and non-pharmacological therapies are crucial for managing the disease. Herbal and natural therapies also show potential as complementary treatments, though additional scientific evidence is required.

Advances in biomarker research, immunotherapy, artificial intelligence, and personalized medicine have opened up fresh possibilities for better diagnosis and treatment. Continuous research and a multidisciplinary approach are essential for improving prevention, early intervention, and sustained management. As science continues to advance, there is hope that more effective treatments and improved outcomes will soon be available for patients and their families.   

REFERENCES

1. DeTure MA, Dickson DW. Neuropathological diagnosis of Alzheimer’s disease and other dementias. Molecular Neurodegeneration. 2019;14:32.
2. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clinical Anatomy. 1995;8:429–431.
3. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nature Reviews Disease Primers. 2015;1:15056.
4. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. European Journal of Neurology. 2018;25:59–70.
5. Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimer’s Research & Therapy. 2017;9:60.
6. Kumar A, Singh A. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacological Reports. 2015;67:195–203.
7. Perl DP. Neuropathology of Alzheimer’s disease. Mount Sinai Journal of Medicine. 2010;77:32–42.
8. Caselli RJ, Beach TG, Knopman DS, Graff-Radford NR. Alzheimer disease: scientific breakthroughs and translational challenges. Mayo Clinic Proceedings. 2017;92:978–994.
9. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253–260.
10. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurology. 2011;10:241–252.
11. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biological Psychiatry. 2015;77:43–51.
12. Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature Genetics. 2019;51:404–413.
13. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurology. 2015;14:388–405.
14. Da Mesquita S, Ferreira AC, Sousa JC, et al. Insights on the pathophysiology of Alzheimer’s disease: the crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience & Biobehavioral Reviews. 2016;68:547–562.
15. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology. 1991;30:572–580.
16. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiology of Aging. 2006;27:1372–1384.
17. Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Archives of Neurology. 1995;52:81–88.
18. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–639.
19. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups. Alzheimer’s & Dementia. 2011;7:263–269.
20. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14:535–562.
21. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Acta Neuropathologica. 2012;123:1–11.
22. Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta Neuropathologica. 2016;131:659–685.
23. Corriveau RA, Koroshetz WJ, Gladman JT, et al. Alzheimer’s disease-related dementias summit 2016: National research priorities. Neurology. 2017;89:2381–2391.
24. Nelson PT, Trojanowski JQ, Abner EL, et al. New old pathologies: AD, PART, and cerebral age-related TDP-43 with sclerosis. Journal of Neuropathology & Experimental Neurology. 2016;75:482–498.
25. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica. 2014;128:755–766.
26. Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica. 2016;131:87–102.
27. Khachaturian ZS. Diagnosis of Alzheimer’s disease. Archives of Neurology. 1985;42:1097–1105.
28. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2012;2:a006171.
29. Lam B, Masellis M, Freedman M, et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimer’s Research & Therapy. 2013;5:1.
30. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397–1403.
31. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease. Alzheimer’s & Dementia. 2011;7:280–292.
32. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer’s & Dementia. 2012;8:1–13.
33. Rodriguez Garcia PL, Rodriguez Garcia D. Diagnosis of vascular cognitive impairment and its main categories. Neurologia. 2015;30:223–239.
34. O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annual Review of Neuroscience. 2011;34:185–204.
35. Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochemical Pharmacology. 2014;88:508–516.
36. Forner S, Baglietto-Vargas D, Martini AC, et al. Synaptic impairment in Alzheimer’s disease: a dysregulated symphony. Trends in Neurosciences. 2017;40:347–357.
37. Vidoni ED, Yeh HW, Morris JK, et al. Cerebral beta-amyloid angiopathy is associated with earlier dementia onset in Alzheimer’s disease. Neurodegenerative Diseases. 2016;16:218–224.
38. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Annals of Neurology. 1997;41:17–24.
39. Boche D, Denham N, Holmes C, Nicoll JA. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer’s disease pathogenesis. Acta Neuropathologica. 2010;120:369–384.
40. Bales KR, O’Neill SM, Pozdnyakov N, et al. Passive immunotherapy targeting amyloid-beta reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain. 2016;139:563–577.
41. Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down’s syndrome. Lancet Neurology. 2016;15:622–636.
42. Malek-Ahmadi M, Perez SE, Chen K, Mufson EJ. Neuritic and diffuse plaque associations with memory in non-cognitively impaired elderly. Journal of Alzheimer’s Disease. 2016;53:1641–1652.
43. Attems J, Yamaguchi H, Saido TC, Thal DR. Capillary CAA and perivascular Abeta-deposition: two distinct features of Alzheimer’s disease pathology. Journal of the Neurological Sciences. 2010;299:155–162.
44. Gold G, Giannakopoulos P, Herrmann FR, et al. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain. 2007;130:2830–2836.
45. Wake H, Moorhouse AJ, Jinno S, et al. Resting microglia directly monitor the functional state of synapses in vivo. Journal of Neuroscience. 2009;29:3974–3980.
46. Steele ML, Robinson SR. Reactive astrocytes give neurons less support: implications for Alzheimer’s disease. Neurobiology of Aging. 2012;33:423.e1–423.e13.
47. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487.
48. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiology of Aging. 2003;24:321–331.
49. Rami L, Sala-Llonch R, Sole-Padulles C, et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer’s disease. Journal of Alzheimer’s Disease. 2012;31:517–526.
50. Cummings J, Aisen P, Lemere C, et al. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Journal of Prevention of Alzheimer’s Disease. 2021;8:98–106.
51. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and splice-site mutations in tau with inherited dementia FTDP-17. Nature. 1998;393:702–705.
52. Apostolova LG, Green AE, Babakchanian S, et al. Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment, and Alzheimer disease. Alzheimer Disease & Associated Disorders. 2012;26:17–27.
53. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics. Lancet Neurology. 2011;10:785–796.
54. Mandal PK, Pettegrew JW, Masliah E, et al. Interaction between Abeta peptide and alpha synuclein in overlapping pathology of Alzheimer’s and Parkinson’s disease. Neurochemical Research. 2006;31:1153–1162.
55. DeTure MA, Dickson DW. Molecular Neurodegeneration review on Alzheimer’s disease pathology and comorbidities. Molecular Neurodegeneration. 2019;14:32.